PPLPHARMA logo

Piramal Pharma Limited Stock Price

NSEI:PPLPHARMA Community·₹216.2b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 14 Fair Values set on narratives written by author

PPLPHARMA Share Price Performance

₹162.84
-58.40 (-26.40%)
₹204.60
Fair Value
₹162.84
-58.40 (-26.40%)
20.4% undervalued intrinsic discount
₹204.60
Fair Value
Price ₹162.84
AnalystConsensusTarget ₹204.60
AnalystLowTarget ₹195.00
AnalystHighTarget ₹310.00

PPLPHARMA Community Narratives

AnalystConsensusTarget·
Fair Value ₹204.6 20.4% undervalued intrinsic discount

Expanding Capacity Will Capture Global Healthcare Demand

0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AnalystLowTarget·
Fair Value ₹195 16.5% undervalued intrinsic discount

CDMO And Complex Hospital Generics Capacity Will Shape A Cautious Yet Balanced Outlook

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystHighTarget·
Fair Value ₹310 47.5% undervalued intrinsic discount

Biopharma Outsourcing And ADC Capacity Will Drive Strong Long Term Upside Potential

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
₹195
16.5% undervalued intrinsic discount
Revenue
13.38% p.a.
Profit Margin
9.43%
Future PE
36.88x
Price in 2029
₹343.58
₹310
47.5% undervalued intrinsic discount
Revenue
15.9% p.a.
Profit Margin
12.66%
Future PE
40.9x
Price in 2028
₹444.43

Trending Discussion

Updated Narratives

PPLPHARMA logo

PPLPHARMA: Future Upside Will Stem From Inhalation Portfolio And Compliance Progress

Fair Value: ₹204.6 20.4% undervalued intrinsic discount
8 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
PPLPHARMA logo

CDMO And Complex Hospital Generics Capacity Will Shape A Cautious Yet Balanced Outlook

Fair Value: ₹195 16.5% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
PPLPHARMA logo

Biopharma Outsourcing And ADC Capacity Will Drive Strong Long Term Upside Potential

Fair Value: ₹310 47.5% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Reasonable growth potential with mediocre balance sheet.

1 Risk
1 Reward

Piramal Pharma Limited Key Details

₹88.7b

Revenue

₹34.6b

Cost of Revenue

₹54.1b

Gross Profit

₹55.7b

Other Expenses

-₹1.6b

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-1.23
60.98%
-1.84%
60.1%
View Full Analysis

About PPLPHARMA

Founded
2020
Employees
5476
CEO
n/a
WebsiteView website
www.piramalpharma.com

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids’ wellness, digestives, women’s health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.

Recent PPLPHARMA News & Updates

Piramal Pharma Limited (NSE:PPLPHARMA) Just Reported Earnings, And Analysts Cut Their Target Price

Jan 31
Piramal Pharma Limited (NSE:PPLPHARMA) Just Reported Earnings, And Analysts Cut Their Target Price

Recent updates

No updates